Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Nutrients ; 9(10)2017 Sep 21.
Article de Anglais | MEDLINE | ID: mdl-28934137

RÉSUMÉ

Although allergic inflammation is characterized by a T helper (Th) 2-dominant immune response, the discovery of a role for new T cell subsets in inflammatory diseases has added an additional layer of complexity to the understanding of the pathogeneses of allergic diseases. We evaluated plasma cytokine profiles in infants with cows' milk allergy (CMA), who were being treated with an elimination diet. In a prospective, randomized and controlled study, infants (aged 8.4 ± 3.9 months) with CMA were treated with an elimination diet for 120 days, which replaced cows' milk with a hydrolysed soy protein formula (n = 26) or a free amino acid formula (n = 20). Blood samples were collected before treatment during active disease (T0) and after 120 days, when symptoms were absent (T1). Plasma cytokine concentrations were measured. Infants with CMA had higher plasma concentrations of interleukin (IL)-4 and IL-13 and lower concentrations of IL-9, IL-17A and interferon-γ, compared with healthy breast-fed infants. At T0, there was a positive correlation between blood eosinophil numbers and plasma concentrations of IL-4, IL-9, IL-17A and IL-22. Treatment with a cows' milk elimination diet resulted in a decrease in plasma IL-4, IL-9, IL-13 and IL-22 and an increase in plasma IL-17A. We conclude that IL-4 and IL-13 are elevated in active CMA. The association of IL-9 and IL-22 with eosinophilia, and the decrease in these two cytokines with cows' milk elimination, suggests that they both play a role in the symptoms observed in CMA and may be important targets for future interventions.


Sujet(s)
Préparation pour nourrissons , Interleukine-9/sang , Interleukines/sang , Hypersensibilité au lait/diétothérapie , Hydrolysats de protéines/administration et posologie , Protéines de soja/administration et posologie , Brésil , Éosinophilie/sang , Éosinophilie/diétothérapie , Éosinophilie/immunologie , Femelle , Humains , Nourrisson , Préparation pour nourrissons/effets indésirables , Interleukine-13/sang , Interleukine-4/sang , Mâle , Hypersensibilité au lait/sang , Hypersensibilité au lait/diagnostic , Hypersensibilité au lait/immunologie , Études prospectives , Hydrolysats de protéines/effets indésirables , Protéines de soja/effets indésirables , Facteurs temps , Résultat thérapeutique , Interleukin-22
2.
Clin Nutr ; 32(4): 599-605, 2013 Aug.
Article de Anglais | MEDLINE | ID: mdl-23260750

RÉSUMÉ

BACKGROUND & AIMS: N-3 fatty acids (FA) may have benefits in ICU patients. The aims were to identify whether FA status is altered in critical illness and to evaluate the effect of supplemental intravenous n-3 FA on plasma FA status and clinical outcome in ICU patients receiving enteral nutrition. METHODS: Enterally fed patients (n = 49; 60-80 years) were recruited in the first 48 h of ICU admission. Fifteen patients received n-3 FA emulsion (0.2 g/kg) over 6 h for 3 consecutive days, and 34 patients did not (control). Samples were collected before supplementation, and 24 and 72 h after the third infusion. Nineteen healthy elderly subjects were also studied; they gave a single blood sample. FA were measured in plasma phosphatidylcholine (PC). RESULTS: Critically ill patients had altered plasma PC FA compared with healthy elderly subjects. Surviving ICU patients had higher levels of docosahexaenoic acid and total n-3 FA and a lower ratio of n-6:n-3 FA in plasma PC than non-survivors. Infusion of n-3 FA increased eicosapentaenoic, docosahexaenoic and total n-3 FA, and decreased arachidonic and total n-6 FA and n-6:n-3 FA and arachidonic:eicosapentaenoic acid ratios. Gas exchange was enhanced 72 h after the third n-3 FA infusion (p = 0.001). CONCLUSIONS: Critically ill patients may have altered plasma FA profiles. A higher total n-3 FA and docosahexaenoic acid content in plasma PC is associated with survival and improved gas exchange.


Sujet(s)
Maladie grave/thérapie , Compléments alimentaires , Nutrition entérale , Acides gras omega-3/administration et posologie , Administration par voie intraveineuse , Sujet âgé , Sujet âgé de 80 ans ou plus , Acide arachidonique/sang , Acide docosahexaénoïque/sang , Acide eicosapentanoïque/sang , Émulsions/analyse , Femelle , Huiles de poisson/administration et posologie , Humains , Unités de soins intensifs , Mâle , Évaluation de l'état nutritionnel , Phosphatidylcholines/sang , Études prospectives , Résultat thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE